INTS Earnings Date: Nov 5, 2026 (Estimated) — Intensity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is INTS's next earnings date?
Intensity Therapeutics, Inc. (INTS) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.94.
How did INTS do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Intensity Therapeutics, Inc. posted EPS of -$1.11 versus the -$0.87 estimate, a miss of 42.3%. Revenue was $0. The stock's 1-day post-earnings move was -2.1%.
How much does INTS stock move after earnings?
INTS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.87 | -1.11 | -42.31% | $0 | ❌ Miss | -2.10% | -3.26% | -6.29% |
| 2026-05-07 | Q1 2026 | -1.14 | -0.96 | +15.79% | $0 | ✅ Beat | -0.39% | -4.11% | -26.03% |
| 2026-03-27 | Q4 2025 | -1.29 | -1.31 | -1.55% | $0 | ❌ Miss | -5.80% | -8.96% | -14.26% |
| 2025-11-06 | Q3 2025 | -0.06 | -0.06 | +0.00% | $0 | ➖ Inline | -6.18% | -1.48% | +3.38% |
| 2025-03-13 | Q4 2024 | -0.23 | -0.22 | +4.35% | $0 | ✅ Beat | -0.22% | -17.00% | -18.72% |
| 2024-11-13 | Q3 2024 | -0.30 | -0.25 | +16.67% | $0 | ✅ Beat | +2.43% | -4.84% | -33.55% |
| 2024-03-14 | Q4 2023 | -0.18 | -0.12 | +33.33% | $0 | ✅ Beat | +15.63% | +32.45% | +0.24% |
| 2023-11-13 | Q3 2023 | -0.09 | -0.17 | -88.89% | $0 | ❌ Miss | +1.84% | -22.79% | +197.06% |
Showing last 8 quarters.